Distinct translatome changes in specific neural populations precede electroencephalographic changes in prion-infected mice

PLoS Pathog. 2022 Aug 12;18(8):e1010747. doi: 10.1371/journal.ppat.1010747. eCollection 2022 Aug.

Abstract

Selective vulnerability is an enigmatic feature of neurodegenerative diseases (NDs), whereby a widely expressed protein causes lesions in specific cell types and brain regions. Using the RiboTag method in mice, translational responses of five neural subtypes to acquired prion disease (PrD) were measured. Pre-onset and disease onset timepoints were chosen based on longitudinal electroencephalography (EEG) that revealed a gradual increase in theta power between 10- and 18-weeks after prion injection, resembling a clinical feature of human PrD. At disease onset, marked by significantly increased theta power and histopathological lesions, mice had pronounced translatome changes in all five cell types despite appearing normal. Remarkably, at a pre-onset stage, prior to EEG and neuropathological changes, we found that 1) translatomes of astrocytes indicated reduced synthesis of ribosomal and mitochondrial components, 2) glutamatergic neurons showed increased expression of cytoskeletal genes, and 3) GABAergic neurons revealed reduced expression of circadian rhythm genes. These data demonstrate that early translatome responses to neurodegeneration emerge prior to conventional markers of disease and are cell type-specific. Therapeutic strategies may need to target multiple pathways in specific populations of cells, early in disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / pathology
  • Electroencephalography
  • Humans
  • Mice
  • Neurons / metabolism
  • Prion Diseases* / pathology
  • Prions* / metabolism

Substances

  • Prions

Grants and funding

This study was supported by internal funding from the German Center for Neurodegenerative Diseases to SB and WSJ (https://www.dzne.de/), and from the Knut and Alice Wallenberg foundation to WSJ (https://kaw.wallenberg.org/en). External funding came from Deutsche Forschungsgemeinschaft (DI 1718/3-1) to LD, and Helmholtz-Alberta Initiative- Neurodegenerative Disease Research (HAI-NDR SO-083) to WSJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.